Autopsy report · NCT02665364

Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

“Reorganization proceedings of the sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 4 years 4 months before it stopped.
• 185 participants enrolled.
• Results were posted on the registry 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Neovacs

Sponsor type

Industry

Conditions

Systemic Lupus Erythematosus

Interventions

IFNα-Kinoid; Placebo; ISA 51 VG

Participants

185

Sites

101

Countries

Argentina, Belgium, Chile, Colombia, Croatia, France, Georgia, Germany, Italy, Mexico, Moldova, Peru and more

Trials that died the same way

• Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer
  “change of sponsor” (69% match in meaning)
• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
  “Sponsor change” (69% match in meaning)
• Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
  “Strategic direction of the sponsor changed” (69% match in meaning)
• A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
  “Sponsor decision based on strategic re-alignment” (68% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.